Embryonic cardiomyocyte, but not autologous stem cell transplantation, restricts infarct expansion, enhances ventricular function, and improves long-term survival.

At day 49, heart function of mice treated with eCMs tended to be better than those treated with SMs (higher EF and larger stroke volume), although differences did not reach statistical significance; this may be also due to the fact that mice with SM and bad LV function had already died.

also in 111,027 other papers